Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | February 01, 2018 | February 05, 2018 |
| Medpace Holdings, Inc.MEDP · Entity 3327 | Director · President & CEO · 10% owner | September 29, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2028-02-01 | Direct | 20,000 |
Reported balance
After 2018-02-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-01 · Grant · Acquired 20,000 · Balance 20,000 F3: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 29,994 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 29,994 |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 1,642,492 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,642,492 F1: The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 268,428 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 268,428 F2: The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein.
F2: The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein.
F3: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Medpace Holdings, Inc.
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 338,225 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-29 · Sale · Disposed 26,701 · Balance 360,191 F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Row 2 · 2026-09-30 · Sale · Disposed 21,966 · Balance 338,225 F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. |
| Common StockSEC Table I · non-derivative | IndirectBy Medpace Investors, LLC | 4,733,019 |
Reported balance
Holding disclosure · report date 2026-09-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,733,019 F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 01:43 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 21,966 | $625.47 | $13,739,074.02 |
DisclosureSEC source: 0001622058-26-000022 · wk-form4_1790890990.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,225 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 01:43 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 26,701 | $621.02 | $16,581,855.02 |
DisclosureSEC source: 0001622058-26-000022 · wk-form4_1790890990.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,191 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| September 28, 2026 Filed Sep 29, 2026 20:13 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 2,410 | $620.07 | $1,494,368.70 |
DisclosureSEC source: 0001622058-26-000020 · wk-form4_1790712800.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 386,892 F1 · kind: The transaction(s) reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $621.20. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| September 25, 2026 Filed Sep 29, 2026 20:13 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 154 | $620.60 | $95,572.40 |
DisclosureSEC source: 0001622058-26-000020 · wk-form4_1790712800.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,302 F1 · kind: The transaction(s) reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:22 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 27,833 | $621.33 | $17,293,477.89 |
DisclosureSEC source: 0001622058-26-000018 · wk-form4_1790367761.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,456 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $625.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 20:22 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 16,083 | $628.64 | $10,110,417.12 |
DisclosureSEC source: 0001622058-26-000018 · wk-form4_1790367761.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,289 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $637.48. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| September 22, 2026 Filed Sep 23, 2026 20:05 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 49,018 | $628.11 | $30,788,695.98 |
DisclosureSEC source: 0001622058-26-000016 · wk-form4_1790193932.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 433,372 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $632.815. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| September 21, 2026 Filed Sep 23, 2026 20:05 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 21,883 | $623.29 | $13,639,455.07 |
DisclosureSEC source: 0001622058-26-000016 · wk-form4_1790193932.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,390 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $625.91. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:23 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 10,880 | $620.40 | $6,749,952.00 |
DisclosureSEC source: 0001622058-26-000014 · wk-form4_1790022182.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 504,273 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.21. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| September 16, 2026 Filed Sep 17, 2026 20:39 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 8,770 | $621.29 | $5,448,713.30 |
DisclosureSEC source: 0001622058-26-000012 · wk-form4_1789677576.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 515,153 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $623.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:39 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 15,971 | $620.84 | $9,915,435.64 |
DisclosureSEC source: 0001622058-26-000012 · wk-form4_1789677576.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,923 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.84. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 20:11 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 650 | $620.27 | $403,175.50 |
DisclosureSEC source: 0001622058-26-000010 · wk-form4_1788207113.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,894 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $621.28. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 20:12 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 4,000 | $620.03 | $2,480,120.00 |
DisclosureSEC source: 0001622058-26-000008 · wk-form4_1787861551.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 540,544 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $620.54. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:12 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 673 | $620.38 | $417,515.74 |
DisclosureSEC source: 0001622058-26-000008 · wk-form4_1787861551.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,544 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $621.89. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 24, 2026 Filed Aug 25, 2026 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 1,983 | $620.23 | $1,229,916.09 |
DisclosureSEC source: 0000892251-26-000152 · form4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,217 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $621.25. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 13,995 | $624.45 | $8,739,177.75 |
DisclosureSEC source: 0000892251-26-000152 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 547,200 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $628.685. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 20:13 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 27,174 | $618.79 | $16,814,999.46 |
DisclosureSEC source: 0000892251-26-000125 · form4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 561,195 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $606.20 to $626.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:13 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 15,609 | $606.47 | $9,466,390.23 |
DisclosureSEC source: 0000892251-26-000125 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 588,369 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $601.29 to $611.42. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 20:18 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 458 | $600.39 | $274,978.62 |
DisclosureSEC source: 0000892251-26-000114 · form4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 603,978 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.345 to $600.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:18 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 11,366 | $601.53 | $6,836,989.98 |
DisclosureSEC source: 0000892251-26-000114 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 604,436 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $603.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 20:28 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 17,610 | $605.11 | $10,655,987.10 |
DisclosureSEC source: 0001622058-26-000006 · wk-form4_1786566512.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615,802 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.09 to $608.185. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:28 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 5,534 | $601.53 | $3,328,867.02 |
DisclosureSEC source: 0001622058-26-000006 · wk-form4_1786566512.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 633,412 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $602.73. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| July 28, 2026 Filed Jul 29, 2026 20:36 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 3,510 | $600.01 | $2,106,035.10 |
DisclosureSEC source: 0001622058-26-000004 · wk-form4_1785357402.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 638,946 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $600.45. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 20:36 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 3,728 | $600.85 | $2,239,968.80 |
DisclosureSEC source: 0001622058-26-000004 · wk-form4_1785357402.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 642,456 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $603.495. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| April 24, 2026 Filed Apr 28, 2026 20:55 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001622058-26-000002 · wk-form4_1777409737.xml · derivative · entry 4 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MEDP common stock. F4 · derivative.exercise_date: The restricted stock units vest in full on the second anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries. F4 · derivative.expiration_date: The restricted stock units vest in full on the second anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries. Read SEC document |
| April 24, 2026 Filed Apr 28, 2026 20:55 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $410.54 | $0.00 |
DisclosureSEC source: 0001622058-26-000002 · wk-form4_1777409737.xml · derivative · entry 3 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-04-24 F2 · derivative.exercise_date: The option vests on the second anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:26 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 668 | $590.69 | $394,580.92 |
DisclosureSEC source: 0001622058-25-000023 · wk-form4_1764883609.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 646,184 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $591.61. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 21:28 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 5,698 | $590.47 | $3,364,498.06 |
DisclosureSEC source: 0001622058-25-000021 · wk-form4_1764797301.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 646,852 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $592.30. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:28 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 23,178 | $593.25 | $13,750,348.50 |
DisclosureSEC source: 0001622058-25-000021 · wk-form4_1764797301.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $596.36. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 21:48 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 15,151 | $593.46 | $8,991,512.46 |
DisclosureSEC source: 0001622058-25-000019 · wk-form4_1764625688.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,728 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $602.78. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:48 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 41,331 | $606.88 | $25,082,957.28 |
DisclosureSEC source: 0001622058-25-000019 · wk-form4_1764625688.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 690,879 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $602.13 to $612.525. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:29 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 42,392 | $615.52 | $26,093,123.84 |
DisclosureSEC source: 0001622058-25-000017 · wk-form4_1764192540.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,210 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $610.50 to $626.545. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:29 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 59,025 | $607.78 | $35,874,214.50 |
DisclosureSEC source: 0001622058-25-000017 · wk-form4_1764192540.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 774,602 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $593.46 to $617.165. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 21:20 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 21,858 | $592.18 | $12,943,870.44 |
DisclosureSEC source: 0001622058-25-000015 · wk-form4_1764019201.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 833,627 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $595.58. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:20 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 6,830 | $598.49 | $4,087,686.70 |
DisclosureSEC source: 0001622058-25-000015 · wk-form4_1764019201.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 855,485 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $604.23. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 21:14 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 23,862 | $592.07 | $14,127,974.34 |
DisclosureSEC source: 0001622058-25-000013 · wk-form4_1763673258.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 862,315 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $594.065. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:14 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 7,191 | $590.84 | $4,248,730.44 |
DisclosureSEC source: 0001622058-25-000013 · wk-form4_1763673258.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 886,177 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $592.09. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:51 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 6,047 | $591.00 | $3,573,777.00 |
DisclosureSEC source: 0001622058-25-000011 · wk-form4_1763502666.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 893,368 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $593.185. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:51 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 14,747 | $595.26 | $8,778,299.22 |
DisclosureSEC source: 0001622058-25-000011 · wk-form4_1763502666.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 899,415 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $600.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:41 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 5,128 | $601.37 | $3,083,825.36 |
DisclosureSEC source: 0001622058-25-000009 · wk-form4_1763156465.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914,162 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $605.21. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:41 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 5,312 | $603.23 | $3,204,357.76 |
DisclosureSEC source: 0001622058-25-000009 · wk-form4_1763156465.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 919,290 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.23 to $605.01. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:10 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 1,197 | $475.11 | $568,706.67 |
DisclosureSEC source: 0001622058-25-000006 · wk-form4_1756930246.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 924,602 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $475.00 to $475.70. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 20:10 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 36,196 | $475.90 | $17,225,676.40 |
DisclosureSEC source: 0001622058-25-000006 · wk-form4_1756930246.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 925,799 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $475.00 to $477.11. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 20:23 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 620 | $475.00 | $294,500.00 |
DisclosureSEC source: 0001622058-25-000004 · wk-form4_1756412601.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 961,995 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. Read SEC document |
| July 28, 2025 Filed Jul 29, 2025 21:37 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 48,487 | $451.69 | $21,901,093.03 |
DisclosureSEC source: 0001668397-25-000097 · wk-form4_1753825051.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 962,615 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $450.00 to $454.96. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 21:47 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 84,770 | $0.00 Strike: $107.93 | $0.00 |
DisclosureSEC source: 0001668397-25-000033 · wk-form4_1741643264.xml · derivative · entry 8 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,770 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 21:47 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 234,259 | $0.00 Strike: $56.61 | $0.00 |
DisclosureSEC source: 0001668397-25-000033 · wk-form4_1741643264.xml · derivative · entry 7 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 234,259 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 21:47 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 37,417 | $0.00 Strike: $54.74 | $0.00 |
DisclosureSEC source: 0001668397-25-000033 · wk-form4_1741643264.xml · derivative · entry 6 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,417 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 21:47 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | Exercise / conversionCommon Stock | 84,770 | $107.93 | $9,149,226.10 |
DisclosureSEC source: 0001668397-25-000033 · wk-form4_1741643264.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,011,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 21:47 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | Exercise / conversionCommon Stock | 234,259 | $56.61 | $13,261,401.99 |
DisclosureSEC source: 0001668397-25-000033 · wk-form4_1741643264.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 926,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.